SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis
JCI Insight · 2023
DOI: 10.1172/jci.insight.154120 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2023. Verfasst von Yuchen Xie und 11 weiteren Autor:innen. Beteiligte Einrichtung: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, USA. Hauptthemen laut MEDLINE: Chromatin, Histone-Lysine N-Methyltransferase, Lung Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS.
Abstract (Originalsprache)
SETD2 , a H3K36 trimethyltransferase, is the most frequently mutated epigenetic modifier in lung adenocarcinoma, with a mutation frequency of approximately 9%. However, how SETD2 loss of function promotes tumorigenesis remains unclear. Using conditional Setd2 -KO mice, we demonstrated that Setd2 deficiency accelerated the initiation of Kras G12D -driven lung tumorigenesis, increased tumor burden, and significantly reduced mouse survival. An integrated chromatin accessibility and transcriptome analysis revealed a potentially novel tumor suppressor model of SETD2 in which SETD2 loss activates intronic enhancers to drive oncogenic transcriptional output, including the KRAS transcriptional signature and PRC2-repressed targets, through regulation of chromatin accessibility and histone chaperone recruitment. Importantly, SETD2 loss sensitized KRAS-mutant lung cancer to inhibition of histone chaperones, the FACT complex, or transcriptional elongation both in vitro and in vivo. Overall, our studies not only provide insight into how SETD2 loss shapes the epigenetic and transcriptional landscape to promote tumorigenesis, but they also identify potential therapeutic strategies for SETD2 mutant cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center (MSKCC), New York, New York, USA.
- Gerstner Sloan Kettering Graduate School of Biomedical Sciences, New York, New York, USA.
- Computational and Systems Biology Program, MSKCC, New York, New York, USA.
- Tri-Institutional Training Program in Computational Biology and Medicine, New York, New York, USA.
- Molecular Oncology, Department of Medicine, Washington University, St. Louis, Missouri, USA.
- Department of Pathology and Laboratory Medicine, MSKCC, New York, New York, USA.
Förderung
- NCI NIH HHS
- NIH HHS
Zitieren
APA
Xie, Y., Sahin, M., Wakamatsu, T., Inoue-Yamauchi, A., Zhao, W., Han, S., Nargund, A. M., Yang, S., Lyu, Y., Hsieh, J. J., Leslie, C. S., & Cheng, E. H. (2023). SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis. JCI Insight. https://doi.org/10.1172/jci.insight.154120
Vancouver
Xie Y, Sahin M, Wakamatsu T, Inoue-Yamauchi A, Zhao W, Han S, et al. SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis. JCI Insight. 2023. doi:10.1172/jci.insight.154120
BibTeX
@article{Xie2023,
author = {Xie, Yuchen and Sahin, Merve and Wakamatsu, Toru and Inoue-Yamauchi, Akane and Zhao, Wanming and Han, Song and Nargund, Amrita M and Yang, Shaoyuan and Lyu, Yang and Hsieh, James J and Leslie, Christina S and Cheng, Emily H},
title = {SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis},
journal = {JCI Insight},
year = {2023},
doi = {10.1172/jci.insight.154120}
}
EUVIMED